Cepheid to Pay Abaxis $17.25M to Settle Infringement Case | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market Tuesday that it has reached a settlement with Abaxis over litigation the firms had filed against each other a couple of yeasr ago.

Abaxis filed suit against Cepheid in June 2010 claiming that the Sunnyvale, Calif.-based firm was infringing certain of its patents and was in breach of a licensing deal between the firms. Abaxis claimed that Cepheid had ceased paying royalties on a license that it took to US Patent No. 5,413,732, which covers reagents used in Cepheid's Xpert MRSA test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.